Facts
The French Football Federation (Fédération Française de Football, FFF) charges respondent M84 for a violation of the Anti-Doping Rules. During a match on February 10, 2012, a sample was taken for doping control purposes. The analysis showed the presence of a metabolite of cannabis. Cannabis is a prohibited substance according the World Anti Doping Agency (WADA) prohibited list and is regarded as a specified substance.

History
The athlete didn't use the cannabis to enhance his sport performance, it was used in occasionally because of personal difficulties.

Decision
1. The sanction is a period of ineligibility of six months in which respondent can't take part in competitions and sporting events organized or authorized by the FFF.
2. The period of ineligibility will be reduced by the period already served by the earlier decision, dated May 14, 2012, of the disciplinary committee of the FFF.
3. The earlier decision (3 months period of ineligibility) dated May 14, 2012, of the disciplinary committee of the FFF will be modified.
4. The decision starts on the date of notification.
5. The decision will be published and sent to the parties involved.

The person didn't show after selection by the anti-doping authorities to supply a urine sample at a competition in Belgium.
Person was heard for the Disciplinary Committee and stated he felt sick during the competition, dropped out en went home. A high number of cyclist dropped out during competition that day because of the high temperatures. The person had already left the competition when the selection started by the anti-doping authorities of the athletes to provide sample.

The Committee noticed an absence in the doping regulations for the situation of ill athletes dropping out of the competition before the selection has started for an anti-doping test.
The Committee decides the fact proven that person felt sick during the race, dropped out of the competition and wasn’t able to provide a urine sample, nor was he able to visit the Doping Control Station. Person can’t be blamed for not showing a medical statement about his illness on the day of the competition. Person is therefore acquitted of violation the Anti-Doping Rules.
Fees and expenses for this committee shall be borne by the Royal Dutch Cycling Federation (Koninklijke Nederlandsche Wieler Unie (KNWU).

Person was selected for an in competition doping control test in Belgium. Person didn't show after selection to provide a sample at the Doping Control Station.
In his defence person stated he dropped out of the competition and left home. This happened before selection started by the anti-doping authorities for a urine test. The authorities also made an error with the selection and announcement of the athletes player's numbers. The autorities didn't use the sound installation to call the person to the Doping Control Station.
It was not possible to hear the Flanders doping officials for the hearing. Person’s statement was considered plausible and was supported by another witness statetement.
The Disciplinary Committee decides to acquit the person of violation the Anti-Doping Rules.

Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update M.S. Bahrke, C.E. Yesalis 3rd, J.E. Wright. - (Sports Medicine 22 (1996) 6 (December) ; p. 367-390)

• PMID: 8969015
• DOI: 10.2165/00007256-199622060-00005

Abstract

Endogenous testosterone levels have been linked to aggressive behaviour in both animals and humans. Studies administering moderate doses of exogenous testosterone for contraceptive and clinical purposes reveal essentially no adverse effects on male sexual and aggressive behaviour. However, investigations and case reports of athletes, usually involving higher doses, demonstrate an association between anabolic-androgenic steroid use and affective and psychotic syndromes and psychological dependence. Efforts to study the psychological and behavioural effects of anabolic-androgenic steroids are complicated by a variety of methodological limitations. Only 3 prospective, blinded studies demonstrating aggression or adverse overt behaviour resulting from anabolic-androgenic steroid use have been reported. With estimates of over 1 million past or current users in the US, an extremely small percentage of individuals using anabolic-androgenic steroids appear to experience mental disturbances severe enough to result in clinical treatment and medical case reports. Even among those so affected, the roles of previous psychiatric history, genetic susceptibility to addictions or mental disorders, environmental and peer influences, and individual expectations remain unclear.

The South African Institute for Drug-Free Sport (SAIDS) has reported an anti-doping rule violation against the Athlete after his sample tested positive for the prohibited substance cannabis.
After notification a provisional suspension was ordered and the Athlete was heard for the SAIDS Disciplinary Panel.

The Athlete admitted the violation and stated that he smoked an OKA piped two days before the competition, which was spiked with cannabis by a friend as act of jealously.

Without intention to enhance his sport performance and with a low degree of fault the SAIDS Disciplinary Panel decides on 23 October 2012 to impose a 3 month period of ineligibility on the Athlete, starting on de date of the notification, i.e. on 11 September 2012.

An anti-doping rule violation has reported against the Player for the use of the prohibited substance 3-hydroxy-4-methoxy-clomiphene, 4-hydroxy-clomiphene,N-desmethyl-4-hydroxy-clomiphene (metabolites of clomiphene).
A provisional suspension was ordered, Player’s request for a Therapeutic Use Exemption (TUE) was rejected and a 2 year period of ineligibility was imposed on the Player. Hereafter Player’s appeal was rejected and the sanction confirmed.

The Player appealed the imposed sanction to the FIBA. The Player filed a statement in his defence and was heard for the FIBA Disciplinary Panel.
Player stated he had used prescribed medication to treat his health problems in the weeks before the doping control. Player did not know the medication could contain a prohibited substance and had no intention to enhance his performance. His two doctor’s confirmed Player’s statement and the use of the prescribed medication.
The Panel finds the Player acted negligently in his responsibility that no prohibited substance enters his body.
He did not research the ingredients of the medication before using it and did not consult a doctor or sport physician about the medication. Considering Player’s statement and the circumstances the FIBA Disciplinary Panel decides to impose a 9 month period of ineligibility on the Player starting on the date of the provisional suspension.

Detection and characterization of urinary metabolites of boldione by LC-MS/MS. Part I: Phase I metabolites excreted free, as glucuronide and sulfate conjugates, and released after alkaline treatment of the urine / C. Gómez, O.J. Pozo, A. Fabregat, J. Marcos, K. Deventer, P. Van Eenoo, J. Segura, R. Ventura

• Drug Testing and Analysis 4 (2012) 10 (October), p. 775-785
• PMID: 23090723
• DOI: 10.1002/dta.1433

Abstract

Boldione (1,4-androstadien-3,17-dione) is included in the list of prohibited substances, issued by the World Anti-Doping Agency (WADA). Endogenous production of low concentrations of boldione has also been reported. The objective of this study was to assess boldione metabolism in humans. Detection of boldione metabolites was accomplished by analysis by liquid chromatography coupled to tandem mass spectrometry of urine samples obtained after administration of the drug and subjected to different sample preparation procedures to analyze the different metabolic fractions (free, glucuronides, sulpfates and released in basic media). In addition to boldione, eight metabolites were detected in the free fraction. Four of them were identified by comparison with standards: 6β-hydroxy-boldenone (M3), androsta-1,4,6-triene-3,17-dione (M5), (5α)-1-androstenedione (M6) and (5α)-1-testosterone (M8). Metabolite M7 was identified as the 5β-isomer of 1-androstenedione, and metabolites M1, M2 and M4 were hydroxylated metabolites and tentative structures were proposed based on mass spectrometric data. After β-glucuronidase hydrolysis, five additional metabolites excreted only as conjugates with glucuronic acid were detected: boldenone, (5β)-1-testosterone (M9), and three metabolites resulting from reduction of the 3-keto group. Boldenone, epiboldenone, and hydroxylated metabolites of boldione, boldenone and 1-testosterone were detected as conjugates with sulfate. In addition, boldione and seven metabolites (boldenone, M2, M3, M4, M5, M7 and M9) increased their concentration in urine after treatment of the urine in alkaline conditions. In summary, 15 boldione metabolites were detected in all fractions. The longer detection time was observed for metabolite M4 after alkaline treatment of the urine, which was detected up to 5 days after boldione administration.

2013 iNADO AGM
NADO Leadership
The Doping List
USADA Reasoned Decision on Lance Armstrong: Media (Re)action

The Puerto Rico Anti-Doping Organisation and the Qatar Anti-Doping Commission are our newest members.
USADA v. Armstrong Media Coverage

Affidavit Paul Scott [USADA vs Lance Armstrong October 10, 2012]
October 9, 2012

Mr. Paul Scott is founder, President and Chief Science Officer of Scott Analytics, a company that provides internal anti-doping programs for professional cyclists and other non cycling events.

Mr. Scott stated to USADA that he helped Floyd Landis to come clean about his use of doping during his cycling career.
On behalf of Floyd Landis he contacted USADA and provided them with statements from Landis about systemic doping on the U.S. Postal Service team, his involment and the involment of several elite cyclists, medical doctors and officials.
Hereafter Floyd Landis had meetings in person with USADA where he relayed the previous information, and additional information regarding his experiences and personal knowledge of doping in cycling.